Abstract

The ability to predict cancer recurrence after surgery is a critical aspect of cancer care, influencing decisions regarding post-operative surveillance and adjuvant therapies. Post-surgical biomarkers, which include genetic, proteomic, and epigenetic markers, provide important insights into the likelihood of recurrence in patients with various types of cancer. These biomarkers can help clinicians identify high-risk patients who may benefit from closer monitoring or additional treatments, ultimately improving patient outcomes. This article discusses the current landscape of post- surgical biomarkers, their predictive capabilities, and the potential for integrating these markers into routine clinical practice for cancer management.